<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0211-6995</journal-id>
<journal-title><![CDATA[Nefrología (Madrid)]]></journal-title>
<abbrev-journal-title><![CDATA[Nefrología (Madr.)]]></abbrev-journal-title>
<issn>0211-6995</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Nefrología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0211-69952016000400397</article-id>
<article-id pub-id-type="doi">10.1016/j.nefro.2015.10.018</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[El índice neutrófilo/linfocito como marcador de disfunción sistémica endotelial en sujetos asintomáticos]]></article-title>
<article-title xml:lang="en"><![CDATA[The neutrophil-to-lymphocyte ratio as a marker of systemic endothelial dysfunction in asymptomatic subjects]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Urbistondo]]></surname>
<given-names><![CDATA[Diego]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Beltrán]]></surname>
<given-names><![CDATA[Almudena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Beloqui]]></surname>
<given-names><![CDATA[Oscar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Huerta]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Clínica Universidad de Navarra Departamento de Medicina Interna ]]></institution>
<addr-line><![CDATA[Pamplona Navarra]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2016</year>
</pub-date>
<volume>36</volume>
<numero>4</numero>
<fpage>397</fpage>
<lpage>403</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S0211-69952016000400397&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S0211-69952016000400397&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S0211-69952016000400397&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Fundamento y objetivo: El índice neutrófilo/linfocito es un marcador inflamatorio de valor pronóstico en enfermedades cardiovasculares. El objetivo del presente trabajo es valorar la asociación entre el índice neutrófilo/linfocito y la alteración del cociente albúmina/creatinina urinario como marcador precoz de disfunción endotelial sistémica asociada a enfermedad microvascular y riesgo cardiovascular, en sujetos asintomáticos.  Materiales y métodos Se realizó un estudio transversal en 1.816 sujetos asintomáticos. Se excluyó del a estudio aquellos pacientes que presentaron antecedentes de enfermedad cardiovascular, los que recibían tratamiento con fármacos antiproteinúricos (inhibidores de la enzima conversora de angiotensina y antagonistas de los receptores de la angiotensina II) y aquellos que presentaron un cociente albúmina/creatinina superior a 300 mg/dL. La variable desenlace del estudio fue la alteración del cociente albúmina/creatinina urinario.  Resultados: El índice neutrófilo/linfocito resultó significativamente asociado a la alteración del cociente albúmina/creatinina urinario, tanto en el estudio univariante como en el multivariante, independientemente de otros cofactores como la edad, la hipertensión arterial, la diabetes, la dislipidemia o el filtrado glomerular patológico. El análisis de la sensibilidad y la especificidad de distintos niveles del índice neutrófilo/linfocito permitió generar 3 grupos de riesgo de alteración del cociente albúmina/creatina urinario: riesgo bajo con un cociente neutrófilo/linfocito &lt; 1,5, riesgo intermedio con cociente neutrófilo/linfocito entre 1,5 y 3 y riesgo alto con un cociente neutrófilo/linfocito &gt; 3. La proporción relativa de alteración del cociente albúmina/creatinina urinario, en los 3 grupos de riesgo, aumentaba en razón del valor del índice neutrófilo/linfocito de forma independiente al resto de cofactores.  Conclusiones: El índice neutrófilo/linfocito surge como un potencial marcador de disfunción endotelial sistémica económico, rápido, no invasivo e independiente de otros factores conocidos, en sujetos asintomáticos.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background and objective: The neutrophil-to-lymphocyte ratio has demonstrated to be a prognostic inflammatory marker in cardiovascular disease. The objective of this study is to evaluate the association between neutrophil-to-lymphocyte ratio and pathologic urinary albumin/creatinine ratio as an early marker of cardiovascular risk and systemic endothelial dysfunction, associated with microvascular disease, in asymptomatic subjects.  Materials and methods: A unicenter cross-sectional study was conducted, including 1816 asymptomatic subjects. Patients with previous cardiovascular disease, those who were treated with ACE inhibitors and/or angiotensin II receptor blockers and patients with albumin/creatinine ratio over 300 mg/g were excluded. The outcome of the study was the presence of a pathologic urinary albumin/creatinine ratio.  Results: The neutrophil-to-lymphocyte ratio was significantly associated with altered urinary albumin/creatinine ratio in the univariate analysis and after adjustment for other known endothelial and cardiovascular risk factors (age, hypertension, dyslipidaemia, diabetes or altered glomerular filtration rate). Based on the sensitivity and specificity of different neutrophil-to-lymphocyte ratio thresholds, 3 risk groups were created for altered urinary albumin/creatinine ratio: low risk in those with neutrophil-to-lymphocyte ratio &lt; 1.5, intermediate risk in patients between 1.5 and 3, and high risk in those with neutrophil-to-lymphocyte ratio &gt; 3. These groups were found to have a statistically significant and independent prognostic power for altered urinary albumin/creatinine ratio in asymptomatic patients.  Conclusions: The neutrophil-to-lymphocyte ratio appears to be a cost-efficient, non-invasive and independent potential marker of systemic endothelial dysfunction in asymptomatic subjects.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Índice neutrófilo/linfocito]]></kwd>
<kwd lng="es"><![CDATA[Cociente albúmina/creatinina urinario]]></kwd>
<kwd lng="es"><![CDATA[Disfunción endotelial]]></kwd>
<kwd lng="es"><![CDATA[Riesgo cardiovascular]]></kwd>
<kwd lng="es"><![CDATA[Sujetos asintomáticos]]></kwd>
<kwd lng="en"><![CDATA[Neutrophil-to-lymphocyte ratio]]></kwd>
<kwd lng="en"><![CDATA[Urinary albumin/creatinine ratio]]></kwd>
<kwd lng="en"><![CDATA[Endothelial dysfunction]]></kwd>
<kwd lng="en"><![CDATA[Cardiovascular risk]]></kwd>
<kwd lng="en"><![CDATA[Asymptomatic subjects]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nichols]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Townsend]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Luengo-Fernandez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Leal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Scarborough]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[European Cardiovascular Disease Statistics 2012]]></source>
<year></year>
<publisher-loc><![CDATA[Brussels ]]></publisher-loc>
<publisher-name><![CDATA[European Heart Network]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice]]></article-title>
<collab>Fifth Joint Task Force of the European Society of Cardiology</collab>
<source><![CDATA[Eur J Prev Cardiol]]></source>
<year>2012</year>
<volume>19</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>585-667</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Surrogate endpoints and renal protection: Focus on microalbuminuria]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Epstein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Parving]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Ruilope]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood Press Suppl]]></source>
<year>1997</year>
<volume>2</volume>
<page-range>52-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Albuminuria reflects widespread vascular damage. The Steno hypothesis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deckert]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Feldt-Rasmussen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Borch-Johnsen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Kofoed-Enevoldsen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Diabetologia]]></source>
<year>1989</year>
<volume>32</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>219-26</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Microalbuminuria: Marker or maker of cardiovascular disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdelhafiz]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmed]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nahas]]></surname>
<given-names><![CDATA[M el]]></given-names>
</name>
</person-group>
<source><![CDATA[Nephron Exp Nephrol]]></source>
<year>2011</year>
<volume>119</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>e6-e10</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Atherosclerosis an inflammatory disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>1999</year>
<volume>340</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>115-26</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inflammation but not endothelial dysfunction is associated with the severity of coronary artery disease in dyslipidemic subjects]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rueda-Clausen]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Jaramillo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Luengas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Oubiña]]></surname>
<given-names><![CDATA[M del Pilar]]></given-names>
</name>
<name>
<surname><![CDATA[Cachofeiro]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lahera]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<source><![CDATA[Mediators Inflamm]]></source>
<year>2009</year>
<page-range>469169</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[What have we learned about the biology of aterosclerosis? The role of inflammation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Libby]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol]]></source>
<year>2001</year>
<volume>88</volume>
<numero>7B</numero>
<issue>7B</issue>
<page-range>3J-6J</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inflammation and cancer: Back to Virchow?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balkwill]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mantovani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2001</year>
<volume>357</volume>
<numero>9255</numero>
<issue>9255</issue>
<page-range>539-45</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inflammation and cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coussens]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Werb]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<source><![CDATA[Nature]]></source>
<year>2002</year>
<volume>420</volume>
<numero>6917</numero>
<issue>6917</issue>
<page-range>860-7</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The systemic inflammation-based neutrophil-lymphocyte ratio: Experience in patients with cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guthrie]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Charles]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Roxburgh]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Horgan]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[McMillan]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<source><![CDATA[Crit Rev Oncol Hematol]]></source>
<year>2013</year>
<volume>88</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>218-30</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tamhane]]></surname>
<given-names><![CDATA[UU]]></given-names>
</name>
<name>
<surname><![CDATA[Aneja]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Montgomery]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[EK]]></given-names>
</name>
<name>
<surname><![CDATA[Eagle]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Gurm]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol]]></source>
<year>2008</year>
<volume>102</volume>
<page-range>653-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Relationship between neutrophil-to-lymphocyte ratio and saphenous vein graft disease in patients with coronary bypass]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Do&#287;an]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Akyel]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Imen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Oksuz]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Elik]]></surname>
<given-names><![CDATA[IE]]></given-names>
</name>
<name>
<surname><![CDATA[Ayturk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Appl Thromb Hemost]]></source>
<year>2015</year>
<volume>21</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Predictive value of elevated neutrophil-lymphocyte ratio on cardiac mortality in patients with stable coronary artery disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Emdin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Passino]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Michelassi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Battaglia]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cocci]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Chim Acta]]></source>
<year>2008</year>
<volume>395</volume>
<page-range>27-31</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Relationship between baseline white blood cell count and degree of coronary artery disease and mortality in patients with acute coronary síndromes: A TACTICS-TIMI 18 (Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy-Thrombolysis in Myocardial Infarction 18 trial) substudy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabatine]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Morrow]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Cannon]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Demopoulos]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[DiBattiste]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Coll Cardiol]]></source>
<year>2002</year>
<volume>40</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1761-8</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Neutrophil-lymphocyte ratio as an important assessment tool]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kurtoglu]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Kucuk]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Demirkol]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ozturk]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Expert Rev Cardiovasc Ther]]></source>
<year>2014</year>
<volume>12</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>537-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The comparative effects of valsartan and amlodipine on vWf levels and N/L ratio in patients with newly diagnosed hypertension]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Karaman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Balta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Seyit Ahmet]]></surname>
<given-names><![CDATA[AY]]></given-names>
</name>
<name>
<surname><![CDATA[Cakar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Naharci]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Demirkol]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Exp Hypertens]]></source>
<year>2013</year>
<volume>35</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>516-22</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)]]></article-title>
<collab>Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults</collab>
<source><![CDATA[JAMA]]></source>
<year>2001</year>
<volume>285</volume>
<page-range>2486-97</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Peng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Endocr Disord]]></source>
<year>2015</year>
<volume>15</volume>
<page-range>9</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwab]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Christensen]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Dougherty]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Klahr]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Intern Med]]></source>
<year>1987</year>
<volume>147</volume>
<page-range>943-4</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cost-benefit analysis and prediction of 24-hour proteinuria from the spot urine protein-creatinine ratio]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chitalia]]></surname>
<given-names><![CDATA[VC]]></given-names>
</name>
<name>
<surname><![CDATA[Kothari]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wells]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Livesey]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Robson]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Searle]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Nephrol]]></source>
<year>2001</year>
<volume>55</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>436-47</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[User's guide to the medical literature III. How to use an article about a diagnostic test: What are the results and will they help me in caring for my patients?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jaeschke]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Guyatt]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
<name>
<surname><![CDATA[Sackett]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
</person-group>
<source><![CDATA[JAMA]]></source>
<year>1994</year>
<volume>271</volume>
<page-range>704</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Beneficial effects of rosuvastatin treatment in patients with metabolic syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bostan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Yildiz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ozkan]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Uzunhasan]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Kaya]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Yigit]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<source><![CDATA[Angiology]]></source>
<year>2015</year>
<volume>66</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>122-7</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inflammatory markers, cholesterol and statins: Pathophysiological role and clinical importance]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Biasucci]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Biasillo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Stefanelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Chem Lab Med]]></source>
<year>2010</year>
<volume>48</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1685-91</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Predictive value of neutrophil to lymphocyte ratio in outcomes of patients with acute coronary syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muhmmed Suliman]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Bahnacy Juma]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Ali Almadhani]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Pathare]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Alkindi]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Uwe Werner]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Med Res]]></source>
<year>2010</year>
<volume>41</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>618-22</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Usefulness of neutrophil-to-lymphocyte ratio in risk stratification of patients with advanced heart failure]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benites-Zapata]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[AV]]></given-names>
</name>
<name>
<surname><![CDATA[Nagarajan]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Cauthen]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Starling]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol]]></source>
<year>2015</year>
<volume>115</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>57-61</page-range></nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of diabetes on neutrophil-to-lymphocyte ratio and its relationship to coronary artery disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verdoia]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Schaffer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Barbieri]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Aimaretti]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Marino]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sinigaglia]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<collab>Novara Atherosclerosis Study Group (NAS)</collab>
<source><![CDATA[Diabetes Metab]]></source>
<year>2015</year>
<volume>41</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>304-11</page-range></nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Neutrophil/lymphocyte ratio is related to the severity of coronary artery disease and clinical outcome in patients undergoing angiography -The growing versatility of NLR]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fowler]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Agha]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<source><![CDATA[Atherosclerosis]]></source>
<year>2013</year>
<volume>228</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>44-5</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Neutrophil lymphocyte ratio significantly improves the Framingham risk score in prediction of coronary heart disease mortality: Insights from the National Health and Nutrition Examination Survey-III]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Parikh]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Badheka]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Deshmukh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Cardiol]]></source>
<year>2014</year>
<volume>171</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>390-7</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Association of epicardial adipose tissue, neutrophil-to-lymphocyte ratio and platelet-to- lymphocyte ratio with diabetic nephropathy]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Akbas]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Demirtas]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ozcicek]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Timuroglu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Bakirci]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Hamur]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Clin Exp Med]]></source>
<year>2014</year>
<volume>7</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1794-801</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The relationship between neutrophil-to-lymphocyte ratio and inflammation in end-stage renal disease patients]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turkmen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Guney]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Yerlikaya]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Tonbul]]></surname>
<given-names><![CDATA[HZ]]></given-names>
</name>
</person-group>
<source><![CDATA[Ren Fail]]></source>
<year>2012</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>155-9</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cardiovascular implications of proteinuria: An indicator of chronic kidney disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agrawal]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Marinescu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Agarwal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[McCullough]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Rev Cardiol]]></source>
<year>2009</year>
<volume>6</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>301-11</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Connection between the early phases of kidney disease and the metabolic syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Landecho]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Colina]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Huerta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fortuño]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Zalba]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Beloqui]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2011</year>
<volume>64</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>373-8</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Circulatory syndrome: An evolution of the metabolic syndrome concept!]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Khoshdel]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Carney]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Gillies]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Cardiol Rev]]></source>
<year>2012</year>
<volume>8</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>68-76</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Proteinuria and its relation to cardiovascular disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Currie]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Delles]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Int J Nephrol Renovasc Dis]]></source>
<year>2013</year>
<volume>7</volume>
<page-range>13-24</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Inflammation and insulin resistance]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shoelson]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Goldfine]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<source><![CDATA[J Clin Invest]]></source>
<year>2006</year>
<volume>116</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1793-801</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Statin therapy may not effect NLR and MPV levels in patients with hypercholesterolemia: A retrospective study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gungoren]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Besli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Caliskan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Polat]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Basar]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Serdar]]></surname>
<given-names><![CDATA[OA]]></given-names>
</name>
</person-group>
<source><![CDATA[Angiology]]></source>
<year>2015</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
